NOVEL has Authored 150+ Peer Reviewed Studies in Top Journals and Conferences

News & Events

NOVEL Health Strategies Won Two Poster Award Finalist Honor at ISPOR Baltimore.

NOVEL Health Strategies Won Two Poster Award Finalist Honor at ISPOR Milan.

NOVEL Health Strategies Wins Another PLATINUM Medal award from AMCP (October 2015)

NOVEL Health Strategies interviewed and quoted for market access challenges for Biosimilars: Regulations not the only barrier to biosimilars in the US say analysts (March 2015)

NOVEL Health Strategies was interviewed and quoted by Fast Company for cover story on most innovative companies of 2015 (March 2015)

NOVEL Health Strategies won two Platinum and Bronze Medal Awards for Presentations at AMCP Nexus Conference in Boston, MA (October 7-10, 2014)

NOVEL Health Strategies Selected for Multiple Presentations at AMCP Nexus Conference in Boston, MA (October 7-10, 2014)

NOVEL Health Strategies Quoted in San Francisco Chronicle Story on Breakthrough Drugs: New FDA process speeds approval of high-priced breakthrough drugs (August 4, 2014)

NOVEL's Interview on Latest Trends and Case Studies for Biosimilars and Biobetters (Biopharma, April 23, 2014)

Interview on FDA's Breakthrough Therapy Designation Trends (Biopharma, April 22, 2014)

Interview on Biologic Market Trends: What Factors are Driving High Growth of Biologic Products (Nature Medicine, May 2012)

Quoted by ACCC: Patient Access Trends for Targeted Cancer Therapies (ACCC Buzz, April 2012)

Interview on Hepatitis C Market Trends: Key Factors for Success of HCV Products (Nature Medicine, January 2012)

Presentation on Trends in Cost Effectiveness Featured as Highlights of the AMCP Meeting

Interview on Market Access and Reimbursement Challenges for Biosimilars and Biobetters (Scientific American, April 2011)

Interview on Regulatory Environment for Genetic Testing (The New York Times, May 2010)

Importance of Sub-population Analysis to Demonstrate Value of Medical Products (The Gray Sheet, April 2010)

Strategies for Gaining US and Global Market Access of Novel Drugs and Devices

Developing Economic Models for NICE, HTAs, Payers, Providers and Other Stakeholders

Biosimilars & Biobetters: Market Access Opportunities and Regulatory Challenges (Novel Health event hosted by The Pink Sheet)

Developing Global Value/AMCP Dossier to Show Cost and Comparative Effectiveness

Developing Oncology HEOR, Marketing, Pricing, Market Access and Reimbursement Strategy

Impact of Global Health Care Reforms on Pricing, Access and Health Outcomes Strategy (Podium Presentation at ISPOR Annual Meeting in Washington DC)

Recent Publications

Indirect Treatment Comparison of Valbenazine and Deutetrabenazine (with Neurocrine Biosciences, Published September 2019-NEW)

Comparative effectiveness review of Valbenazine and Tetrabenazine (with Neurocrine Biosciences)

Systematic review and pooled meta-analysis for Defibrotide (with Jazz Pharmaceuticals)

Study on need for treatment with biologics for early Crohn's disease patients (with Abbvie)

Systematic Review on Hepatitis C Demonstrating Value of Treatment (With Abbvie).

Meta-Analysis and Economic Model for a Johnson & Johnson Device (October 2015, PDF of the Paper)

Strategy Overview on Breakthrough Therapy Designations in Nature Biotechnology, April 2014

What's Fueling the Biotech Engine-2012 to 2013: Strategy Perspective on More than Hundred Branded Biotech Products (January 2014, Nature Biotechnology | Top 5 Most Downloaded Articles; Annual Recurring Series Since 2006)

Special Report: Top Strategy Mishaps of 2011-2012, Lessons and Implications for 2013-2020 (February 2013)

What's Fueling the Biotech Engine-2011 to 2012: Strategy Perspective on More than Hundred Branded Biotech Products (December 2012, Nature Biotechnology)

Overview of Clinical, Business and Reimbursement Trends for Targeted Cancer Therapies in Nature Reviews (More Than 20,000 Downloads)

Emerging Role of Biomarkers for Success of Targeted Therapies : Invited Key Note Lecture at BIOVISION (Lyon, France)

Trends In Use of Health Economic Evidence For Developing Clinical Guidelines (2015)

Patient Reported Outcomes In Glaucoma A Systematic Review (2015)

Systematic Review of Epidemiology And Burden of Pancreatic Cancer (2015)

Systematic Review of Epidemiology And Burden of Cutaneous T-Cell Lymphoma (2015)

Overview And Importance of NUB Process For Market Access of In-Patient Drugs And Devices In Germany (2015)

Impact of 2014 Essential Health Benefit Benchmark Plans On Us Managed Care (2015)

Impact of New Changes Due To Affordable Care Act On Us Market Access (2015)

Comparative Effectiveness, Approval Rates And Pricing of Drugs With FDA's Breakthrough Therapy Designations (2015)

Comparison of Ultra Orphan And Cancer Drug Pricing In The US And The UK (2015)

Systematic Review of Cost Effectiveness of Ultra-Orphan Therapies: Lesson Learned From Published HTAs And Studies (Podium Presentation, 2015)

Cost Effectiveness Trends of High Budget Impact Drugs(Podium Presentation at ISPOR Annual Meeting in Washington DC)

Cancer Drug Access Trends and Role of Patient Assistance Programs (ACCC Annual Meeting)

CMS increases reimbursement for CAR-T therapies

Canada to drop United States and Switzerland from price referencing

Canada conditionally recommends Lutathera

Note: For Full List of Our 200+ Publications or for In-Person Replay of Events Email Us at

info@NovelHealthStrategies.com

Podium & Poster Presentations at HTAi 2013 Seoul, Korea

At the Health Technology Assessment HTAi Annual 2013 Meeting in Seoul, Korea, NOVEL's team was selected for podium and poster presentation.

Strategy Overview on Breakthrough Therapy Designations

NOVEL just published a comprehensive overview on all Breakthrough Therapy Designated products, covering their clinical, HEOR, and comparative effectiveness.

NOVEL Won Two Platinum and Bronze Medal Awards at AMCP

NOVEL's team won two Platinum and Bronze Medal Awards for Presentations at AMCP Nexus Educational Conference at Boston.

Nineteen Presentations at ISPOR 2013 New Orleans

NOVEL's team presented nineteen studies on HEOR and market access trends at the 18th Annual International ISPOR meeting in New Orleans.

Annual Strategy Perspective in Nature Biotechnology

Our annual strategy series has been cited and quoted more than two hundred times. JUST PUBLISHED latest article in January 2014 issue.

Market Access & Reimbursement Strategy Seminar in Copenhagen

NOVEL's team and leading stakeholders hosted a 1 day workshop on Market Access & Reimbursement Strategy in Copenhagen.